Enrocin Flavoured Tablets 15 mg

Composition

Active substance:

Each tablet contains:

Enrofloxacin 15.0 mg

For the full list of excipients, see section 6.1.

6.1 List of excipients

Lactose monohydrate

Maize starch

Microcrystalline cellulose

Povidone

Magnesium stearate

Silica colloidal anhydrous

Artificial powdered flavour

3

Pharmaceutical form

Tablet.

Off white to light brown coloured, round tablets, debossed with 'FL' on one side and ‘15’ on other side.

3

Pharmacological properties

Pharmacotherapeutic group: Antibacterials for systemic use, fluoroquinolones

ATC vet code: QJ01MA90.

5.1 Pharmacodynamic properties

Enrofloxacin is bactericidal in action with activity against Gram-positive and Gram- negative bacteria and mycoplasmas. The mechanism of action of the quinolones is unique among antimicrobials – they act primarily to inhibit bacterial DNA gyrase, an enzyme responsible for controlling the supercoiling of bacterial DNA during replication. Resealing of the double standard helix is inhibited resulting in irreversible degradation of the chromosomal DNA. The fluoroquinolones also possess activity against bacteria in the stationary phase by an alteration of the permeability of the outer membrane phospholipid cell wall.

Resistance to fluoroquinolones has been reported to arise from five sources, (i) point mutations in the genes encoding for DNA gyrase and/or topoisomerase IV leading to alterations of the respective enzyme, (ii) alterations of drug permeability in Gram negative bacteria, (iii) efflux mechanisms, (iv) plasmid mediated resistance and (v) gyrase protecting proteins. All mechanisms lead to a reduced susceptibility of the bacteria to fluoroquinolones. Cross-resistance within the fluoroquinolone class of antimicrobials is common.

5.2 Pharmacokinetic particulars

The pharmacokinetics of enrofloxacin in dogs and cats are such that oral and parenteral administration leads to similar serum levels. Enrofloxacin possesses a high distribution volume. Tissue levels 2-3 times higher than that found in the serum, have been demonstrated in laboratory animals and target species. Organs in which high levels can be expected are the lungs, liver, kidney, skin, bone and lymphatic system. Enrofloxacin also distributes into the cerebrospinal fluid, the aqueous humour and the foetus in pregnant animals.

3

Target species

Dogs and cats

3

Indications

The product is for use in dogs and cats in the treatment of bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

3

Dosage

The dosage rate of enrofloxacin is 5 mg/kg given orally once daily or as a divided dose twice daily for 3 to 10 days with or without food.

The daily dose is achieved as follows:

Cats and small dogs: one 15 mg tablet per 3 kg bodyweight.

The 15 mg tablets are not divisible.

3

Contraindications

Not for use in dogs less than 1 year of age or in exceptionally large breeds of dog with a longer growth period under 18 months of age, as articular cartilage may be affected during the period of rapid growth.

Not recommended for use in cats less than 8 weeks of age.

The product should not be used for prophylaxis.

3

Adverse reactions

During the period of rapid growth, enrofloxacin may affect articular cartilage development.

3

Warnings

Special precautions for use in animals

Do not exceed the recommended dosage

Retinotoxic effects including blindness can occur in cats when the recommended dose is exceeded.

Official and local antimicrobial policies should be taken into account when the product is used.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.

Whenever possible, fluoroquinolones should only be used based on susceptibility testing.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to (fluoro)quinolones should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Other precautions

None.

3

Use during pregnancy, lactation or lay

The product may be used safely in pregnant and lactating animals.

3

Interactions

None known.

3

Overdose

Do not exceed the recommended dose. In accidental overdose, vomiting, diarrhoea and CNS/behavioural changes may occur. There is no antidote and treatment should be symptomatic.

In target animal studies, cats have been shown to suffer ocular damage after receiving doses of more than 15 mg/kg once daily for 21 consecutive days. Doses of 30 mg/kg given once daily for 21 consecutive days have been shown to cause irreversible ocular damage. At 50 mg/kg given once daily for 21 consecutive days, blindness can occur.

3

Special warnings

None.

3

Withdrawal period

Not applicable.

3

Incompatibilities

Not applicable

3

Immediate packaging

3

Storage

This veterinary medicinal product does not require any special temperature storage conditions.

Keep the blister in the outer carton.

3

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

3

Disposal of unused product

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

3

Additional information

Vm 53540/4000

9 DATE OF FIRST AUTHORISATION

01 March 2022

10 DATE OF REVISION OF THE TEXT

March 2022

3

Registration holder

Felix Pharmaceuticals PVT Limited

25-28 North Wall Quay

Dublin 1

D01H104

Ireland

3